Реферат подготовлен по статье «COVID-19 Vaccines», опубликованной на сайте https://emedicine.medscape.com/article/2500139-overview

1.    Coronavirus Vaccine Tracker. The New York Times. https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html. Accessed: March 18, 2021.

2.    McClung N, Chamberland M, Kinlaw K et al. The Advisory Committee on Immunization Practices' Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine – United States, 2020. MMWR Morb Mortal Wkly Rep 2020; 69 (47): 1782–6.

3.    Thanh Le T, Andreadakis Z, Kumar A et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; 19 (5): 305–6.

4.    Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med 2020; 382 (21): 1969–73.

5.    Koirala A, Joo YJ, Khatami A et al. Vaccines for COVID-19: The current state of play. Paediatr Respir Rev 2020; 35: 43–9.

6.    Jeyanathan M, Afkhami S, Smaill F et al. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol 2020; 20 (10): 615–32.

7.    Polack FP, Thomas SJ, Kitchin N, and the, C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383 (27): 2603–15.

8.    Pfizer and BioNTech confirm high efficacy and no serious safety concerns through up to 6 months following second dose in updated topline analysis of landmark COVID-19 vaccine study. Pfizer 2021. Apr 01. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-effi...

9.    Amit S, Regev-Yochay G, Afek A et al. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet 2021; 397 (10277): 875–7.

10. Dagan N, Barda N, Kepten E et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med 202; 384:1412–23.

11. Baden RL, El Sahly HM, Essink B, and the, COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384 (5): 403–16.

12. Moderna provides clinical and supply updates on COVID-19 vaccine program ahead of 2nd annual vaccines day. Moderna 2021. Apr 14. https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-clinical-and-sup...

13. Doria-Rose N, Suthar MS, Makowski M, and the, mRNA-1273 Study Group. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med 2021. Apr 6 [Epub ahead of print].

14. Wu K, Choi A, Koch M et al. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. bioRxiv 2021. Apr 13.

15. Sadoff J, Le Gars M, Shukarev G et al. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med 2021. Jan 13 [Epub ahead of print].

16. COVID-19 vaccine Ad26.COV2.S Sponsor Briefing Document for the FDA Vaccines and Related Biological Products advisory Committee. US Food and Drug Administration. https://www.fda.gov/media/146217/download. Accessed: February 26, 2021.

17. Keech C, Albert G, Cho I et al. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med 2020; 383 (24): 2320–32.

18. Novavax confirms high levels of efficacy against original and variant COVID-19 strains in United Kingdom and South Africa Trials. Novavax 2021. Mar 11. https://ir.novavax.com/news-releases/news-release-details/novavax-confirms-high-levels-efficacy-agai...

19. Voysey M, Clemens SAC, Madhi SA, and the, Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397 (10269): 99–111.

20. Robbins R, Mueller B. After Admitting Mistake, AstraZeneca Faces Difficult Questions about Its Vaccine. The New York Times 2020. Nov 25. https://www.nytimes.com/2020/11/25/business/coronavirus-vaccine-astrazeneca-oxford.html

21. Voysey M, Costa Clemens SA, Madhi SA, and the, Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021; 397 (10277): 881–91.

22. Safety, immunogenicity, and efficacy of INO-4800 for COVID-19 in healthy seronegative adults at high risk of SARS-CoV-2 Exposure. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04642638. Accessed: December 9, 2020.

23. Tebas, P, Yang S, Boyer JD et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, phase 1 clinical trial. E Clinical Medicine 2020. Dec 23. DOI: 10.1016/j.eclinm.2020.100689

24. CVnCoV – CureVac’s mRNA-based vaccine candidate against COVID-19. CureVac. https://www.curevac.com/en/covid-19. Accessed: February 3, 2021.

25. Sanofi and GSK initiate new phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate. Sanofi 2021. Feb 22. https://www.sanofi.com/en/media-room/press-releases/2021/2021-02-22-11-40-00.

26. Clover and Dynavax announce planned global phase 2/3 efficacy trial of adjuvanted COVID-19 vaccine candidate. Dynavax 2021. Feb 01. https://investors.dynavax.com/news-releases/news-release-details/clover-and-dynavax-announce-planned...

27. A study to evaluate the safety, tolerability, and immunogenicity of UB-612 COVID-19 vaccine. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04545749. Accessed: December 14, 2020.

28. HaloVax – VaxCelerate. Hoth Therapeutics. https://hoththerapeutics.com/pipeline/halo-vax/. Accessed: November 21, 2020.

29. Ufovax announces its self-assembling nanoparticles as the next-generation vaccine solution for COVID-19. Ufovax 2020. Sep 17. https://www.ufovax.com/ufovax-announces-its-self-assembling-nanoparticles-as-the-next-generation-vac...

30. PDS Pipeline Overview – Infectious Disease (PDS0203). PDS Biotechnology. https://www.pdsbiotech.com/pipeline/infectious-disease. Accessed: November 21, 2020.

31. Medicago and GSK announce start of phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate. Medicago 2020. Nov 12. https://www.medicago.com/en/newsroom/medicago-and-gsk-announce-start-of-phase-2-3-clinical-trials-of...

32. Ocugen’s COVID-19 vaccine codevelopment partner, Bharat Biotech shares phase 3 interim results of Covaxin, demonstrates efficacy of 81%. Ocugen, Inc. 2021. Mar 03. https://ir.ocugen.com/node/9341/pdf

33. Zhu FC, Guan XH, Li YH et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 396 (10249): 479–88.

34. Piecemeal data releases threaten to undermine Sinovac's COVID-19 vaccine. Reuters. 2020 Dec 28. https://www.reuters.com/article/us-health-coronavirus-sinovac/piecemeal-data-releases-threaten-to-un...

35. Logunov DY, Dolzhikova IV, Shcheblyakov DV et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021. Feb 02.

36. ImmunityBio and NantKwest announce FDA authorization to study hAd5 T-cell COVID-19 vaccine for combination of subcutaneous, oral and sublingual boost to induce T-cell, mucosal, and antibody immunity. Immunity Bio, Inc. 2021. Feb 11. https://immunitybio.com/immunitybio-and-nantkwest-announce-fda-authorization-to-study-had5-t-cell-co...

37. Sanofi’s mRNA COVID-19 vaccine candidate not ready this year – CEO. Reuters 2021. Feb 13. https://www.reuters.com/article/uk-health-coronavirus-sanofi-vaccines-idUKKBN2AD0PT.

38. AnGes and Brickell Biotech Announce a Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 in the U.S. Brickell Biotech 2020. Sep 08. https://ir.brickellbio.com/news/detail/35/anges-and-brickell-biotech-announce-a-collaboration

39. SARS-CoV-2 spike ferritin nanoparticle (spFN) vaccine with ALFQ adjuvant for prevention of COVID-19 in healthy adults. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04784767. Accessed: April 5, 2021.

40. Merck discontinues development of SARS-CoV-2/COVID-19 vaccine candidates; continues development of two investigational therapeutic candidates. Merck 2020. Jan 25. https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-...

41. Galloway SE, Paul P, MacCannell DR et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage – United States, December 29, 2020-January 12, 2021. MMWR Morb Mortal Wkly Rep 2021; 70 (3): 95–9.

42. Xie X, Zou J, Fontes-Garfias CR et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. bioRxiv 2021. Jan 7. DOI: 10.1101/2021.01.07.425740

43. Liu Y, Liu J, Xia H et al. Neutralizing Activity of BNT162b2-Elicited Serum – Preliminary Report. N Engl J Med 2021. Feb 17. DOI: 10.1056/NEJMc2102017

44. Muik A, Wallisch AK, Sänger B et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science 2021; 371 (6534): 1152–3. DOI: 10.1126/science.abg6105

45. Tada T, Dcosta BM, Samanovic-Golden M et al. Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. bioRxiv 2021. Feb 7. DOI: 10.1101/2021.02.05.430003

46. Wu K, Werner AP, Koch M et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. N Engl J Med 2021. Mar 17. DOI: 10.1056/NEJMc2102179

47. Emary KRW, Golubchik T, Aley PK, and the, COVID-19 Genomics UK consortium, AMPHEUS Project., et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet 2021. Mar 30.

48. Madhi SA, Baillie V, Cutland CL, and the, NGS-SA Group Wits-VIDA COVID Group. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med 2021. Mar 16.